Metabolic syndrome: Anesthesia for morbid obesity

Current Opinion in Anaesthesiology

Volumn 23, Issue 3, 2010, Pages 375-383

  Neligan, Patrick J ^a,b  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Atelectasis; Bariatric surgery; BiPAP; CPAP; Metabolic syndrome; NASH; Obesity; Obstructive sleep apnea; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DESFLURANE; FENTANYL; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; KETOROLAC; MORPHINE; NICOTINIC ACID; PROPOFOL; VECURONIUM;

ADVERSE OUTCOME; ANESTHESIA; ATELECTASIS; BARIATRIC SURGERY; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MEGADOSE; ENDOTRACHEAL INTUBATION; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; HYPOXEMIA; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PATIENT POSITIONING; POSITIVE END EXPIRATORY PRESSURE; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; SURGICAL MORTALITY; SURGICAL RISK; UVULOPALATOPHARYNGOPLASTY; WAIST CIRCUMFERENCE;

ANESTHESIA; CARDIOVASCULAR DISEASES; HUMANS; INTUBATION, INTRATRACHEAL; METABOLIC SYNDROME X; OBESITY, MORBID; PULMONARY ATELECTASIS; RESPIRATION, ARTIFICIAL; SLEEP APNEA, OBSTRUCTIVE;

EID: 77951979945     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328338caa0     Document Type: Review

References (122)

1. Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008; 32: 1431-1437.
2. Zaninotto P, Head J, Stamatakis E, et al. Trends in obesity among adults in England from 1993 to 2004 by age and social class and projections of prevalence to 2012. J Epidemiol Community Health 2009; 63: 140-146.
3. Stamatakis E, Zaninotto P, Falaschetti E, et al. Time trends in childhood and adolescent obesity in England from 1995 to 2007 and projections of prevalence to 2015. J Epidemiol Community Health 2010; 64: 167-174.
4. Matthews CE, Sui X, Lamonte MJ, et al. Metabolic syndrome and risk of death • from cancers of the digestive system. Metabolism 2009 [Epub ahead of print]. This study enrolled 33230 men over 14 years. Abdominal obesity [HR = 1.89 (1.36-2.62)] and high glucose [HR = 1.38 (1.02-1.87)] - metabolic syndrome - were independently associated with cancer mortality.
5. Bjorntorp P. Aging and body composition. Nutrition 1997; 13: 572-573.
6. Wang Y, Rimm EB, Stampfer MJ, et al. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005; 81: 555-563.
7. Folsom AR, Kaye SA, Sellers TA, et al. Body fat distribution and 5-year risk of death in older women. JAMA 1993; 269: 483-487.
8. Yusuf S, Hawken S, Èunpuu S, et al. Obesity and the risk of myocardial infarction in 27, 000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649.
9. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38.
10. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and •• risk of death in Europe. N Engl J Med 2008; 359: 2105-2120. This study of 359387 participants from nine countries. Waist circumference and waist-to-hip ratio were strongly associated with the risk of death.
11. Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, lowcarbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003; 77: 43-50.
12. Tushuizen ME, Bunck MC, Pouwels PJ, et al. Pancreatic fat content and betacell function in men with and without type 2 diabetes. Diabetes Care 2007; 30: 2916-2921.
13. Boucher A, Lu D, Burgess SC, et al. Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and reversal with a malate analogue. J Biol Chem 2004; 279: 27263-27271.
14. Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008; 51: 1781-1789.
15. Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-lowenergy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr 2006; 84: 304-311.
16. Hollingsworth KG, Abubacker MZ, Joubert I, et al. Low-carbohydrate diet induced reduction of hepatic lipid content observed with a rapid noninvasive MRI technique. Br J Radiol 2006; 79: 712-715.
17. Petersen KF, Dufour S, Befroy D, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603-608.
18. Juurinen L, Kotronen A, Graner M, Yki-Jarvinen H. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J Clin Endocrinol Metab 2008; 93: 118-124.
19. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
20. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117.
21. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905.
22. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
23. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 45-62.
24. Day CP. Nonalcoholic fatty liver disease: current concepts and management strategies. Clin Med 2006; 6: 19-25.
25. Schindhelm RK, Dekker JM, Nijpels G, et al. No independent association of alanine aminotransferase with risk of future type 2 diabetes in the Hoorn study. Diabetes Care 2005; 28: 2812.
26. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
27. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173.
28. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3.
29. Martyn JA, Kaneki M, Yasuhara S. Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. Anesthesiology 2008; 109: 137-148.
30. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304. (Pubitemid 41242486)
31. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood pressure in adults (Adult Treatment Panel III) : final report. Circulation 2002; 106: 3143.
32. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitusand its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
33. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association. Circulation 2004; 109: 433-438.
34. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
35. Grundy S, Hansen B, Smith S. AHA/NHLBI/ADA conference proceedings: clinical management of metabolic syndrome. Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation 2004; 109: 551.
36. Ford E, Giles W. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003; 26: 575.
37. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U. S. adults. Diabetes Care 2004; 27:+++++ 2444-2449.
38. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
39. Karelis AD, St Pierre DH, Conus F, et al. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004; 89: 2569-2575.
40. Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 2004; 109: 706-713.
41. Girman C, Rhodes T, Mercuri M. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex-CAPS). Am J Cardiol 2004; 93: 136.
42. McNeill AM, Katz R, Girman CJ, et al. Metabolic syndrome and cardiovascular disease in older people: the cardiovascular health study. J Am Geriatr Soc 2006; 54: 1317-1324.
43. Huang KC, Lee LT, Chen CY, Sung PK. All-cause and cardiovascular disease mortality increased with metabolic syndrome in Taiwanese. Obesity (Silver Spring) 2008; 16: 684-689.
44. Wilson PW, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
45. Mozaffarian D, Kamineni A, Prineas RJ, Siscovick DS. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med 2008; 168: 969-978.
46. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666-673.
47. Kurl S, Laukkanen JA, Niskanen L, et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006; 37: 806-811.
48. Pan W, Hindler K, Lee VV, et al. Obesity in diabetic patients undergoing coronary artery bypass graft surgery is associated with increased postoperative morbidity. Anesthesiology 2006; 104: 441-447.
49. Birkmeyer NJ, Charlesworth DC, Hernandez F, et al. Obesity and risk of adverse outcomes associated with coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 1998; 97: 1689-1694.
50. Jin R, Grunkemeier GL, Furnary AP, Handy JR Jr. Is obesity a risk factor for mortality in coronary artery bypass surgery? Circulation 2005; 111: 3359-3365.
51. Kim J, Hammar N, Jakobsson K, et al. Obesity and the risk of early and late mortality after coronary artery bypass graft surgery. Am Heart J 2003; 146: 555-560.
52. Reeves BC, Ascione R, Chamberlain MH, Angelini GD. Effect of body mass index on early outcomes in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2003; 42: 668-676.
53. Prabhakar G, Haan CK, Peterson ED, et al. The risks of moderate and extreme obesity for coronary artery bypass grafting outcomes: a study from the Society of Thoracic Surgeons' database. Ann Thorac Surg 2002; 74: 1125-1130.
54. The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. •• Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361: 445-454 This is a longitudinal study of 4776 patients who had bariatric surgery. It is the largest study to date of perioperative complications. The 30-day mortality rate was 0.3%. The incidence of major complications was 4.3%.
55. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005; 46: 1978-1985.
56. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 45-62.
57. Mangano DT, Layug EL, Wallace A, Tateo I, The Multicenter Study of Perioperative Ischemia Research Group. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 1996; 335: 1713-1721.
58. Poldermans D, Boersma E, Bax JJ, et al., The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999; 341: 1789-1794.
59. Yang H, Raymer K, Butler R, et al. The effects of perioperative [beta]-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J 2006; 152: 983-990.
60. Juul AB, Wetterslev J, Gluud C, et al. Effect of perioperative beta blockade in patients with diabetes undergoing major noncardiac surgery: randomised placebo controlled, blinded multicentre trial. Br Med J 2006; 332: 1482.
61. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing noncardiac surgery (POISE trial) : a randomised controlled trial. Lancet 2008; 371: 1839-1847.
62. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) : multicentre randomised placebocontrolled trial. Lancet 2004; 364: 685-696.
63. Schouten O, Boersma E, Hoeks SE, et al., the Dutch Echocardiographic •• Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009; 361: 980-989. This is the first major prospective study to demonstrate improved perioperative outcomes in patients associated with statin therapy.
64. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004; 39: 967-975.
65. Hindler K, Shaw AD, Samuels J, et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006; 105: 1260-1272.
66. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107: 1848-1851.
67. Lindenauer PK, Pekow P, Wang K, et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004; 291: 2092-2099.
68. O'Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 2005; 45: 336-342.
69. Kapoor AS, Kanji H, Buckingham J, et al. Strength of evidence for perioperative use of statins to reduce cardiovascular risk: systematic review of controlled studies. Br Med J 2006; 333: 1149.
70. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446-1452.
71. Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004; 140: 857-866.
72. Le MY, Godet G, Coriat P, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 2007; 104: 1326-1333.
73. Schouten O, Hoeks SE, Welten GM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007; 100: 316-320.
74. Zerr KJ, Furnary AP, Grunkemeier GL, et al. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997; 63: 356-361.
75. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67: 352-360.
76. Furnary AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 125: 1007-1021.
77. Van den BG, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367.
78. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449-461.
79. The NICE-SUGAR Study Investigators. Intensive versus conventional glu-•• cose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297. This large prospective trial has finally resolved the controversy regarding tight glycemic control in critical illness. There was no benefit associated with intensive insulin therapy. However, the intervention group had a 6.3% absolute risk increase of severe hypoglycemia.
80. Frey WC, Pilcher J. Obstructive sleep-related breathing disorders in patients evaluated for bariatric surgery. Obes Surg 2003; 13: 676-683.
81. O'Keeffe T, Patterson EJ. Evidence supporting routine polysomnography before bariatric surgery. Obes Surg 2004; 14: 23-26.
82. Gross JB, Bachenberg KL, Benumof JL, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology 2006; 104: 1081-1093.
83. Kaw R, Michota F, Jaffer A, et al. Unrecognized sleep apnea in the surgical patient: implications for the perioperative setting. Chest 2006; 129: 198-205.
84. Nowbar S, Burkart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med 2004; 116: 1-7.
85. Rose DK, Cohen MM. The airway: problems and predictions in 18500 patients. Can J Anaesth 1994; 41: 372-383.
86. Ezri T, Warters RD, Szmuk P, et al. The incidence of class 'zero' airway and the impact of Mallampati score, age, sex, and body mass index on prediction of laryngoscopy grade. Anesth Analg 2001; 93: 1073-1075.
87. Juvin P, Lavaut E, Dupont H, et al. Difficult tracheal intubation is more common in obese than in lean patients. Anesth Analg 2003; 97: 595-600. (Pubitemid 36899772)
88. Adnet F, Borron SW, Racine SX, et al. The intubation difficulty scale (IDS) : proposal and evaluation of a new score characterizing the complexity of endotracheal intubation. Anesthesiology 1997; 87: 1290-1297.
89. Brodsky JB, Lemmens HJ, Brock-Utne JG, et al. Morbid obesity and tracheal intubation. Anesth Analg 2002; 94: 732-736.
90. Gonzalez H, Minville V, Delanoue K, et al. The importance of increased neck circumference to intubation difficulties in obese patients. Anesth Analg 2008; 106: 1132-1136.
91. Lundstrom LH, Moller AM, Rosenstock C, et al. High body mass index is a •• weak predictor for difficult and failed tracheal intubation: a cohort study of 91, 332 consecutive patients scheduled for direct laryngoscopy registered in the Danish Anesthesia Database. Anesthesiology 2009; 110: 266-274. This large database study has provided us with population-based data regarding difficult intubation in obese patients.
92. Ezri T, Gewurtz G, Sessler DI, et al. Prediction of difficult laryngoscopy in obese patients by ultrasound quantification of anterior neck soft tissue. Anaesthesia 2003; 58: 1111-1114.
93. Hiremath AS, Hillman DR, James AL, et al. Relationship between difficult tracheal intubation and obstructive sleep apnoea. Br J Anaesth 1998; 80: 606-611.
94. Siyam MA, Benhamou D. Difficult endotracheal intubation in patients with sleep apnea syndrome. Anesth Analg 2002; 95: 1098-1102.
95. Kim JA, Lee JJ. Preoperative predictors of difficult intubation in patients with obstructive sleep apnea syndrome. Can J Anaesth 2006; 53: 393-397.
96. Neligan PJ, Porter S, Max B, et al. Obstructive sleep apnea is not a risk factor • for difficult intubation in morbidly obese patients. Anesth Analg 2009; 109: 1182-1186. This study demonstrated a difficult intubation rate of 3.3% and a difficult laryngoscopy rate of 8.8%. Note, however, that all patients in this study were intubated in the 'ramped' position.
97. Collins JS, Lemmens HJ, Brodsky JB, et al. Laryngoscopy and morbid obesity: a comparison of the 'sniff and 'ramped' positions. Obes Surg 2004; 14: 1171-1175.
98. Greenland KB, Eley V, Edwards MJ, et al. The origins of the sniffing position and the Three Axes Alignment Theory for direct laryngoscopy. Anaesth Intensive Care 2008; 36 (Suppl 1) : 23-27.
99. Pelosi P, Croci M, Ravagnan I, et al. The effects of body mass on lung volumes, respiratory mechanics, and gas exchange during general anesthesia. Anesth Analg 1998; 87: 654-660. (Pubitemid 28397493)
100. Xue FS, Li BW, Zhang GS, et al. The influence of surgical sites on early postoperative hypoxemia in adults undergoing elective surgery. Anesth Analg 1999; 88: 213-219.
101. von Ungern-Sternberg BS, Regli A, Schneider MC, et al. Effect of obesity and site of surgery on perioperative lung volumes. Br J Anaesth 2004; 92: 202-207.
102. Eichenberger A, Proietti S, Wicky S, et al. Morbid obesity and postoperative pulmonary atelectasis: an underestimated problem. Anesth Analg 2002; 95: 1788-1792.
103. Ahmad S, Nagle A, McCarthy RJ, et al. Postoperative hypoxemia in morbidly obese patients with and without obstructive sleep apnea undergoing laparoscopic bariatric surgery. Anesth Analg 2008; 107: 138-143.
104. Coussa M, Proietti S, Schnyder P, et al. Prevention of atelectasis formation during the induction of general anesthesia in morbidly obese patients. Anesth Analg 2004; 98: 1491-1495.
105. Gander S, Frascarolo P, Suter M, et al. Positive end-expiratory pressure during induction of general anesthesia increases duration of nonhypoxic apnea in morbidly obese patients. Anesth Analg 2005; 100: 580-584.
106. Pelosi P, Ravagnan I, Giurati G, et al. Positive end-expiratory pressure improves respiratory function in obese but not in normal subjects during anesthesia and paralysis. Anesthesiology 1999; 91: 1221-1231.
107. Yoshino J, Akata T, Takahashi S. Intraoperative changes in arterial oxygenation during volume-controlled mechanical ventilation in modestly obese patients undergoing laparotomies with general anesthesia. Acta Anaesthesiol Scand 2003; 47: 742-750.
108. Tusman G, Bohm SH, Melkun F, et al. Effects of the alveolar recruitment manoeuver and PEEP on arterial oxygenation in anesthetized obese patients. Rev Esp Anestesiol Reanim 2002; 49: 177-183.
109. 2O.
110. 2O was better than a recruitment maneuver or ZEEP alone.
111. Chalhoub V, Yazigi A, Sleilaty G, et al. Effect of vital capacity manoeuvres on arterial oxygenation in morbidly obese patients undergoing open bariatric surgery. Eur J Anaesthesiol 2007; 24.
112. Perilli V, Sollazzi L, Modesti C, et al. Comparison of positive end-expiratory pressure with reverse Trendelenburg position in morbidly obese patients undergoing bariatric surgery: effects on hemodynamics and pulmonary gas exchange. Obes Surg 2003; 13: 605-609.
113. Sprung J, Whalley DG, Falcone T, et al. The effects of tidal volume and respiratory rate on oxygenation and respiratory mechanics during laparoscopy in morbidly obese patients. Anesth Analg 2003; 97: 268-274.
114. Neligan PJ, Malhotra G, Fraser M, et al. Continuous positive airway pressure • via the Boussignac system immediately after extubation improves lung function in morbidly obese patients with obstructive sleep apnea undergoing laparoscopic bariatric surgery. Anesthesiology 2009; 110: 878-884. This study demonstrates that there is significant loss of lung volume following extubation and this can be prevented by administering CPAP immediately following extubation.
115. Jensen C, Tejirian T, Lewis C, et al. Postoperative CPAP and BiPAP use can be safely omitted after laparoscopic Roux-en-Y gastric bypass. Surg Obesity Related Dis 2008; 4: 512-514.
116. Ahmad S, Nagle A, McCarthy RJ, et al. Postoperative hypoxemia in morbidly obese patients with and without obstructive sleep apnea undergoing laparoscopic bariatric surgery. Anesth Analg 2008; 107: 138-143.
117. Ramirez A, Lalor PF, Szomstein S, Rosenthal RJ. Continuous positive airway pressure in immediate postoperative period after laparoscopic Roux-en-Y gastric bypass: is it safe? Surg Obes Relat Dis 2009; 5: 544-546.
118. Ebeo CT, Benotti PN, Byrd RP Jr, et al. The effect of bi-level positive airway pressure on postoperative pulmonary function following gastric surgery for obesity. Respir Med 2002; 96: 672-676.
119. Kindgen-Milles D, Muller E, Buhl R, et al. Nasal-continuous positive airway pressure reduces pulmonary morbidity and length of hospital stay following thoracoabdominal aortic surgery. Chest 2005; 128: 821-828.
120. Squadrone V, Coha M, Cerutti E, et al., for the Piedmont Intensive Care Units Network. Continuous positive airway pressure for treatment of postoperative hypoxemia: a randomized controlled trial. JAMA 2005; 293: 589-595. (Pubitemid 40171241)
121. Neligan PJ, Malhotra G, Fraser M, et al. Noninvasive ventilation immediately following extubation improves lung function in morbidly obese patients with obstructive sleep apnea undergoing laparoscopic bariatric surgery. Anesth Analg (in press).
122. Joris JL, Sottiaux TM, Chiche JD, et al. Effect of bi-level positive airway pressure (BiPAP) nasal ventilation on the postoperative pulmonary restrictive syndrome in obese patients undergoing gastroplasty. Chest 1997; 111: 665-670.